跳转至内容
Merck
CN

890850O

Avanti

18:1 DAP

Avanti Research - A Croda Brand

别名:

1,2-二油酰-3-二甲基铵-丙烷(DODAP)

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C41H77NO4
化学文摘社编号:
分子量:
648.05
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C41H77NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,39H,5-18,23-38H2,1-4H3/b21-19-,22-20-

InChI key

NYDLOCKCVISJKK-WRBBJXAJSA-N

SMILES string

[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O

assay

>99% (TLC)

form

liquid

packaging

pkg of 2 × 100 mg (890850O-200mg), pkg of 1 × 25 mg (890850O-25mg)

manufacturer/tradename

Avanti Research - A Croda Brand

lipid type

cationic lipids
transfection

shipped in

dry ice

storage temp.

−20°C

正在寻找类似产品? 访问 产品对比指南

General description

18:1 DAP是一种阳离子脂质,制备阳离子脂质体。

Application

18:1 DAP适用于:
  • 作为脂质双分子层的组分
  • 制备稳定的核酸脂质囊泡
  • 含反义寡脱氧核糖核苷酸(ODN)的叶酸(FA)靶向脂质体和非靶向脂质体的制备和理化特性表征

Packaging

5 mL透明玻璃密封安瓿瓶(890850O-200mg)
5 mL透明玻璃密封安瓿瓶(890850O-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

存储类别

10 - Combustible liquids

wgk

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12(Suppl), 3-3 (2013)
Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持